GOOGL, DPZ, PEP: Goldman Sachs Names the Best Stocks to Buy Now
U.S. investment bank Goldman Sachs (GS) has published a list of stocks that it feels can help investors weather the current ...
GOOGL, DPZ, PEP: Goldman Sachs Names Best Stocks to Buy Now
U.S. investment bank Goldman Sachs (GS) has published a list of stocks that it feels can help investors weather the current ...
Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson
Today, Zacks Investment Ideas feature highlights Gilead Sciences GILD and Johnson & Johnson JNJ. Buy Gilead Sciences (GILD ...
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To
We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...
Gilead Sciences's Options: A Look at What the Big Money is Thinking
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
News-Medical.Net on MSN11h
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
The Financial Express11h
Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
BioPharma Dive6h
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Fierce Pharma1d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Le Lézard10h
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...